Characterization of a Nanovaccine Platform Based on an α1,2- Mannobiose Derivative Shows Species-non-specific Targeting to Human, Bovine, Mouse, and Teleost Fish Dendritic Cells

Autores
Pappalardo, Juan Sebastián; Salmaso, Stefano; Levchenko, Tatyana S.; Mastrotto, Francesca; Bersani, Sara; Vermeulen, Monica; Ghersa, Federica; Quattrocchi, Valeria; Zamorano, Patricia Ines; Hartner, William C.; Toniutti, Micaela; Musacchio, Tiziana; Torchilin, Vladimir P.
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Dendritic cells serve as the main immune cells that trigger the immune response. We developed a simple and cost-effective nanovaccine platform based on the α1′,2-mannobiose derivative for dendritic cell targeting. In previous work, we have formulated the α1,2-mannobiose-based nanovaccine platform with plasmid DNA and tested it in cattle against BoHV-1 infection. There, we have shown that the dendritic cell targeting using this nanovaccine platform in vivo can boost the immunogenicity, resulting in a longlasting immunity. In this work, we aim to characterize the α1′,2-mannobiose derivative, which is key in the nanovaccine platform. This DC-targeting strategy takes advantage of the specific receptor known as DC-SIGN and exploits its capacity to bind α1,2-mannobiose that is present at terminal ends of oligosaccharides in certain viruses, bacteria, and other pathogens. The oxidative conjugation of α1′,2-mannobiose to NH2-PEG2kDa-DSPE allowed us to preserve the chemical structure of the non-reducing mannose of the disaccharide and the OH groups and the stereochemistry of all carbons of the reducing mannose involved in the binding to DC-SIGN. Here, we show specific targeting to DC-SIGN of decorated micelles incubated with the Raji/DC-SIGN cell line and uptake of targeted liposomes that took place in human, bovine, mouse, and teleost fish DCs in vitro, by flow cytometry. Specific targeting was found in all cultures, demonstrating a species-non-specific avidity for this ligand, which opens up the possibility of using this nanoplatform to develop new vaccines for various species, including humans.
Estación Experimental Agropecuaria Bariloche
Fil: Pappalardo, Juan Sebastián. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bariloche; Argentina
Fil: Pappalardo, Juan Sebastián. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Instituto de Investigaciones Forestales y Agropecuarias Bariloche; Argentina
Fil: Pappalardo, Juan Sebastián. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Pappalardo, Juan Sebastián. Northeastern University. Center for Pharmaceutical Biotechnology and Nanomedicine; Estados Unidos
Fil: Salmaso, Stefano. University of Padova. School of Medicine. Department of Pharmaceutical and Pharmacological Sciences; Italia
Fil: Levchenko, Tatyana S. Northeastern University. Center for Pharmaceutical Biotechnology and Nanomedicine; Estados Unidos
Fil: Mastrotto, Francesca. University of Padova. School of Medicine. Department of Pharmaceutical and Pharmacological Sciences; Italia
Fil: Bersani, Sara. University of Padova. School of Medicine. Department of Pharmaceutical and Pharmacological Sciences; Italia
Fil: Vermeulen, Monica. Consejo Nacional de Investigaciones Cientificas y Tecnicas; Argentina
Fil: Vermeulen, Monica. Academia Nacional de Medicina. Instituto de Medicina Experimental; Argentina
Fil: Ghersa, Federica. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bariloche; Argentina
Fil: Ghersa, Federica. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Instituto de Investigaciones Forestales y Agropecuarias Bariloche; Argentina
Fil: Ghersa, Federica. Universidad Nacional del Comahue. Instituto de Investigaciones en Biodiversidad y Medioambiente; Argentina
Fil: Quattrocchi, Valeria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Zamorano, Patricia Ines. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Zamorano, Patricia Ines. Consejo Nacional de Investigaciones Cientificas y Tecnicas; Argentina
Fil: Hartner, William C. Northeastern University. Center for Pharmaceutical Biotechnology and Nanomedicine; Estados Unidos
Fil: Toniutti, Micaela. Northeastern University. Center for Pharmaceutical Biotechnology and Nanomedicine; Estados Unidos
Fil: Musacchio, Tiziana. Northeastern University. Center for Pharmaceutical Biotechnology and Nanomedicine; Estados Unidos
Fil: Torchilin, Vladimir P. Northeastern University. Center for Pharmaceutical Biotechnology and Nanomedicine; Estados Unidos
Fuente
Molecular pharmaceutics 18 (7) : 2540-2555 (Julio 2021)
Materia
Nanomedicina
Vacuna
Antígenos
Respuesta Inmunológica
Nanomedicine
Vaccines
Antigens
Immune Response
Nanovacuna
Células Dendríticas
Nivel de accesibilidad
acceso restringido
Condiciones de uso
Repositorio
INTA Digital (INTA)
Institución
Instituto Nacional de Tecnología Agropecuaria
OAI Identificador
oai:localhost:20.500.12123/9742
Acceder
id INTADig_348406d6702d0e2cc5cfa7a5dd9b0308
oai_identifier_str oai:localhost:20.500.12123/9742
network_acronym_str INTADig
repository_id_str l
network_name_str INTA Digital (INTA)
spelling Characterization of a Nanovaccine Platform Based on an α1,2- Mannobiose Derivative Shows Species-non-specific Targeting to Human, Bovine, Mouse, and Teleost Fish Dendritic CellsPappalardo, Juan SebastiánSalmaso, StefanoLevchenko, Tatyana S.Mastrotto, FrancescaBersani, SaraVermeulen, MonicaGhersa, FedericaQuattrocchi, ValeriaZamorano, Patricia InesHartner, William C.Toniutti, MicaelaMusacchio, TizianaTorchilin, Vladimir P.NanomedicinaVacunaAntígenosRespuesta InmunológicaNanomedicineVaccinesAntigensImmune ResponseNanovacunaCélulas DendríticasDendritic cells serve as the main immune cells that trigger the immune response. We developed a simple and cost-effective nanovaccine platform based on the α1′,2-mannobiose derivative for dendritic cell targeting. In previous work, we have formulated the α1,2-mannobiose-based nanovaccine platform with plasmid DNA and tested it in cattle against BoHV-1 infection. There, we have shown that the dendritic cell targeting using this nanovaccine platform in vivo can boost the immunogenicity, resulting in a longlasting immunity. In this work, we aim to characterize the α1′,2-mannobiose derivative, which is key in the nanovaccine platform. This DC-targeting strategy takes advantage of the specific receptor known as DC-SIGN and exploits its capacity to bind α1,2-mannobiose that is present at terminal ends of oligosaccharides in certain viruses, bacteria, and other pathogens. The oxidative conjugation of α1′,2-mannobiose to NH2-PEG2kDa-DSPE allowed us to preserve the chemical structure of the non-reducing mannose of the disaccharide and the OH groups and the stereochemistry of all carbons of the reducing mannose involved in the binding to DC-SIGN. Here, we show specific targeting to DC-SIGN of decorated micelles incubated with the Raji/DC-SIGN cell line and uptake of targeted liposomes that took place in human, bovine, mouse, and teleost fish DCs in vitro, by flow cytometry. Specific targeting was found in all cultures, demonstrating a species-non-specific avidity for this ligand, which opens up the possibility of using this nanoplatform to develop new vaccines for various species, including humans.Estación Experimental Agropecuaria BarilocheFil: Pappalardo, Juan Sebastián. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bariloche; ArgentinaFil: Pappalardo, Juan Sebastián. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Instituto de Investigaciones Forestales y Agropecuarias Bariloche; ArgentinaFil: Pappalardo, Juan Sebastián. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Pappalardo, Juan Sebastián. Northeastern University. Center for Pharmaceutical Biotechnology and Nanomedicine; Estados UnidosFil: Salmaso, Stefano. University of Padova. School of Medicine. Department of Pharmaceutical and Pharmacological Sciences; ItaliaFil: Levchenko, Tatyana S. Northeastern University. Center for Pharmaceutical Biotechnology and Nanomedicine; Estados UnidosFil: Mastrotto, Francesca. University of Padova. School of Medicine. Department of Pharmaceutical and Pharmacological Sciences; ItaliaFil: Bersani, Sara. University of Padova. School of Medicine. Department of Pharmaceutical and Pharmacological Sciences; ItaliaFil: Vermeulen, Monica. Consejo Nacional de Investigaciones Cientificas y Tecnicas; ArgentinaFil: Vermeulen, Monica. Academia Nacional de Medicina. Instituto de Medicina Experimental; ArgentinaFil: Ghersa, Federica. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bariloche; ArgentinaFil: Ghersa, Federica. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Instituto de Investigaciones Forestales y Agropecuarias Bariloche; ArgentinaFil: Ghersa, Federica. Universidad Nacional del Comahue. Instituto de Investigaciones en Biodiversidad y Medioambiente; ArgentinaFil: Quattrocchi, Valeria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Zamorano, Patricia Ines. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Zamorano, Patricia Ines. Consejo Nacional de Investigaciones Cientificas y Tecnicas; ArgentinaFil: Hartner, William C. Northeastern University. Center for Pharmaceutical Biotechnology and Nanomedicine; Estados UnidosFil: Toniutti, Micaela. Northeastern University. Center for Pharmaceutical Biotechnology and Nanomedicine; Estados UnidosFil: Musacchio, Tiziana. Northeastern University. Center for Pharmaceutical Biotechnology and Nanomedicine; Estados UnidosFil: Torchilin, Vladimir P. Northeastern University. Center for Pharmaceutical Biotechnology and Nanomedicine; Estados UnidosACS Publications2021-07-06T17:11:03Z2021-07-06T17:11:03Z2021-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://hdl.handle.net/20.500.12123/9742https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.1c000481543-8384https://doi.org/10.1021/acs.molpharmaceut.1c00048Molecular pharmaceutics 18 (7) : 2540-2555 (Julio 2021)reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repograntAgreement/INTA/PNBIO-1131032/AR./Desarrollo de herramientas biotecnológicas para la prevención y el control de enfermedades pecuarias: vacunas, diagnóstico y eIdemiología molecular.info:eu-repograntAgreement/INTA/2019-PD-E5-I102-001/2019-PD-E5-I102-001/AR./Desarrollo de vacunas y tecnologías para mejorar las estrategias profilácticas y terapéuticas de las enfermedades que afectan la producción animal y la salud públicainfo:eu-repo/semantics/restrictedAccess2025-09-29T13:45:16Zoai:localhost:20.500.12123/9742instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-09-29 13:45:16.807INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse
dc.title.none.fl_str_mv Characterization of a Nanovaccine Platform Based on an α1,2- Mannobiose Derivative Shows Species-non-specific Targeting to Human, Bovine, Mouse, and Teleost Fish Dendritic Cells
title Characterization of a Nanovaccine Platform Based on an α1,2- Mannobiose Derivative Shows Species-non-specific Targeting to Human, Bovine, Mouse, and Teleost Fish Dendritic Cells
spellingShingle Characterization of a Nanovaccine Platform Based on an α1,2- Mannobiose Derivative Shows Species-non-specific Targeting to Human, Bovine, Mouse, and Teleost Fish Dendritic Cells
Pappalardo, Juan Sebastián
Nanomedicina
Vacuna
Antígenos
Respuesta Inmunológica
Nanomedicine
Vaccines
Antigens
Immune Response
Nanovacuna
Células Dendríticas
title_short Characterization of a Nanovaccine Platform Based on an α1,2- Mannobiose Derivative Shows Species-non-specific Targeting to Human, Bovine, Mouse, and Teleost Fish Dendritic Cells
title_full Characterization of a Nanovaccine Platform Based on an α1,2- Mannobiose Derivative Shows Species-non-specific Targeting to Human, Bovine, Mouse, and Teleost Fish Dendritic Cells
title_fullStr Characterization of a Nanovaccine Platform Based on an α1,2- Mannobiose Derivative Shows Species-non-specific Targeting to Human, Bovine, Mouse, and Teleost Fish Dendritic Cells
title_full_unstemmed Characterization of a Nanovaccine Platform Based on an α1,2- Mannobiose Derivative Shows Species-non-specific Targeting to Human, Bovine, Mouse, and Teleost Fish Dendritic Cells
title_sort Characterization of a Nanovaccine Platform Based on an α1,2- Mannobiose Derivative Shows Species-non-specific Targeting to Human, Bovine, Mouse, and Teleost Fish Dendritic Cells
dc.creator.none.fl_str_mv Pappalardo, Juan Sebastián
Salmaso, Stefano
Levchenko, Tatyana S.
Mastrotto, Francesca
Bersani, Sara
Vermeulen, Monica
Ghersa, Federica
Quattrocchi, Valeria
Zamorano, Patricia Ines
Hartner, William C.
Toniutti, Micaela
Musacchio, Tiziana
Torchilin, Vladimir P.
author Pappalardo, Juan Sebastián
author_facet Pappalardo, Juan Sebastián
Salmaso, Stefano
Levchenko, Tatyana S.
Mastrotto, Francesca
Bersani, Sara
Vermeulen, Monica
Ghersa, Federica
Quattrocchi, Valeria
Zamorano, Patricia Ines
Hartner, William C.
Toniutti, Micaela
Musacchio, Tiziana
Torchilin, Vladimir P.
author_role author
author2 Salmaso, Stefano
Levchenko, Tatyana S.
Mastrotto, Francesca
Bersani, Sara
Vermeulen, Monica
Ghersa, Federica
Quattrocchi, Valeria
Zamorano, Patricia Ines
Hartner, William C.
Toniutti, Micaela
Musacchio, Tiziana
Torchilin, Vladimir P.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Nanomedicina
Vacuna
Antígenos
Respuesta Inmunológica
Nanomedicine
Vaccines
Antigens
Immune Response
Nanovacuna
Células Dendríticas
topic Nanomedicina
Vacuna
Antígenos
Respuesta Inmunológica
Nanomedicine
Vaccines
Antigens
Immune Response
Nanovacuna
Células Dendríticas
dc.description.none.fl_txt_mv Dendritic cells serve as the main immune cells that trigger the immune response. We developed a simple and cost-effective nanovaccine platform based on the α1′,2-mannobiose derivative for dendritic cell targeting. In previous work, we have formulated the α1,2-mannobiose-based nanovaccine platform with plasmid DNA and tested it in cattle against BoHV-1 infection. There, we have shown that the dendritic cell targeting using this nanovaccine platform in vivo can boost the immunogenicity, resulting in a longlasting immunity. In this work, we aim to characterize the α1′,2-mannobiose derivative, which is key in the nanovaccine platform. This DC-targeting strategy takes advantage of the specific receptor known as DC-SIGN and exploits its capacity to bind α1,2-mannobiose that is present at terminal ends of oligosaccharides in certain viruses, bacteria, and other pathogens. The oxidative conjugation of α1′,2-mannobiose to NH2-PEG2kDa-DSPE allowed us to preserve the chemical structure of the non-reducing mannose of the disaccharide and the OH groups and the stereochemistry of all carbons of the reducing mannose involved in the binding to DC-SIGN. Here, we show specific targeting to DC-SIGN of decorated micelles incubated with the Raji/DC-SIGN cell line and uptake of targeted liposomes that took place in human, bovine, mouse, and teleost fish DCs in vitro, by flow cytometry. Specific targeting was found in all cultures, demonstrating a species-non-specific avidity for this ligand, which opens up the possibility of using this nanoplatform to develop new vaccines for various species, including humans.
Estación Experimental Agropecuaria Bariloche
Fil: Pappalardo, Juan Sebastián. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bariloche; Argentina
Fil: Pappalardo, Juan Sebastián. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Instituto de Investigaciones Forestales y Agropecuarias Bariloche; Argentina
Fil: Pappalardo, Juan Sebastián. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Pappalardo, Juan Sebastián. Northeastern University. Center for Pharmaceutical Biotechnology and Nanomedicine; Estados Unidos
Fil: Salmaso, Stefano. University of Padova. School of Medicine. Department of Pharmaceutical and Pharmacological Sciences; Italia
Fil: Levchenko, Tatyana S. Northeastern University. Center for Pharmaceutical Biotechnology and Nanomedicine; Estados Unidos
Fil: Mastrotto, Francesca. University of Padova. School of Medicine. Department of Pharmaceutical and Pharmacological Sciences; Italia
Fil: Bersani, Sara. University of Padova. School of Medicine. Department of Pharmaceutical and Pharmacological Sciences; Italia
Fil: Vermeulen, Monica. Consejo Nacional de Investigaciones Cientificas y Tecnicas; Argentina
Fil: Vermeulen, Monica. Academia Nacional de Medicina. Instituto de Medicina Experimental; Argentina
Fil: Ghersa, Federica. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bariloche; Argentina
Fil: Ghersa, Federica. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Instituto de Investigaciones Forestales y Agropecuarias Bariloche; Argentina
Fil: Ghersa, Federica. Universidad Nacional del Comahue. Instituto de Investigaciones en Biodiversidad y Medioambiente; Argentina
Fil: Quattrocchi, Valeria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Zamorano, Patricia Ines. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Zamorano, Patricia Ines. Consejo Nacional de Investigaciones Cientificas y Tecnicas; Argentina
Fil: Hartner, William C. Northeastern University. Center for Pharmaceutical Biotechnology and Nanomedicine; Estados Unidos
Fil: Toniutti, Micaela. Northeastern University. Center for Pharmaceutical Biotechnology and Nanomedicine; Estados Unidos
Fil: Musacchio, Tiziana. Northeastern University. Center for Pharmaceutical Biotechnology and Nanomedicine; Estados Unidos
Fil: Torchilin, Vladimir P. Northeastern University. Center for Pharmaceutical Biotechnology and Nanomedicine; Estados Unidos
description Dendritic cells serve as the main immune cells that trigger the immune response. We developed a simple and cost-effective nanovaccine platform based on the α1′,2-mannobiose derivative for dendritic cell targeting. In previous work, we have formulated the α1,2-mannobiose-based nanovaccine platform with plasmid DNA and tested it in cattle against BoHV-1 infection. There, we have shown that the dendritic cell targeting using this nanovaccine platform in vivo can boost the immunogenicity, resulting in a longlasting immunity. In this work, we aim to characterize the α1′,2-mannobiose derivative, which is key in the nanovaccine platform. This DC-targeting strategy takes advantage of the specific receptor known as DC-SIGN and exploits its capacity to bind α1,2-mannobiose that is present at terminal ends of oligosaccharides in certain viruses, bacteria, and other pathogens. The oxidative conjugation of α1′,2-mannobiose to NH2-PEG2kDa-DSPE allowed us to preserve the chemical structure of the non-reducing mannose of the disaccharide and the OH groups and the stereochemistry of all carbons of the reducing mannose involved in the binding to DC-SIGN. Here, we show specific targeting to DC-SIGN of decorated micelles incubated with the Raji/DC-SIGN cell line and uptake of targeted liposomes that took place in human, bovine, mouse, and teleost fish DCs in vitro, by flow cytometry. Specific targeting was found in all cultures, demonstrating a species-non-specific avidity for this ligand, which opens up the possibility of using this nanoplatform to develop new vaccines for various species, including humans.
publishDate 2021
dc.date.none.fl_str_mv 2021-07-06T17:11:03Z
2021-07-06T17:11:03Z
2021-07
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12123/9742
https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.1c00048
1543-8384
https://doi.org/10.1021/acs.molpharmaceut.1c00048
url http://hdl.handle.net/20.500.12123/9742
https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.1c00048
https://doi.org/10.1021/acs.molpharmaceut.1c00048
identifier_str_mv 1543-8384
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repograntAgreement/INTA/PNBIO-1131032/AR./Desarrollo de herramientas biotecnológicas para la prevención y el control de enfermedades pecuarias: vacunas, diagnóstico y eIdemiología molecular.
info:eu-repograntAgreement/INTA/2019-PD-E5-I102-001/2019-PD-E5-I102-001/AR./Desarrollo de vacunas y tecnologías para mejorar las estrategias profilácticas y terapéuticas de las enfermedades que afectan la producción animal y la salud pública
dc.rights.none.fl_str_mv info:eu-repo/semantics/restrictedAccess
eu_rights_str_mv restrictedAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv ACS Publications
publisher.none.fl_str_mv ACS Publications
dc.source.none.fl_str_mv Molecular pharmaceutics 18 (7) : 2540-2555 (Julio 2021)
reponame:INTA Digital (INTA)
instname:Instituto Nacional de Tecnología Agropecuaria
reponame_str INTA Digital (INTA)
collection INTA Digital (INTA)
instname_str Instituto Nacional de Tecnología Agropecuaria
repository.name.fl_str_mv INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria
repository.mail.fl_str_mv tripaldi.nicolas@inta.gob.ar
_version_ 1844619155351797760
score 12.559606

Publicaciones similares